

Dear Chris

Bevacizumab, sorafenib, sunitinib (second-line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma:

Thank you for the opportunity to comment on the Appraisal Consultation Document and Evaluation Report for the above appraisal.

I wish to confirm that the Department of Health has no substantive comments to make, regarding this consultation.

Many thanks and best wishes



NICE Liaison Team

Department of Health